Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

por Yasaka, Masahiro, Ikushima, Ippei, Harada, Akiko, Imazu, Susumu, Taniguchi, Atsushi, Norris, Stephen, Gansser, Dietmar, Stangier, Joachim, Schmohl, Michael, Reilly, Paul A.
Publicado 2017

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

por Norris, Stephen, Ramael, Steven, Ikushima, Ippei, Haazen, Wouter, Harada, Akiko, Moschetti, Viktoria, Imazu, Susumu, Reilly, Paul A., Lang, Benjamin, Stangier, Joachim, Glund, Stephan
Publicado 2017